AUPH

Aurinia Pharmaceuticals Inc

AUPH, USA

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

https://www.auriniapharma.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
AUPH
stock
AUPH

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Average Recommendation of "Hold" from Analysts MarketBeat

Read more →
AUPH
stock
AUPH

Ritholtz Wealth Management Buys Shares of 84,515 Aurinia Pharmaceuticals Inc $AUPH MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$16.6667

Analyst Picks

Strong Buy

3

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Medium

26.52

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

5.47

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

8.63 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Medium

5.98 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

60.41 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

High

0.44

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 40.19% of the total shares of Aurinia Pharmaceuticals Inc

1.

TANG CAPITAL MANAGEMENT LLC

(7.6195%)

since

2025/06/30

2.

BlackRock Inc

(5.8446%)

since

2025/06/30

3.

NEA Management Company, LLC

(3.0159%)

since

2025/06/30

4.

iShares Russell 2000 ETF

(2.1843%)

since

2025/08/31

5.

State Street Corp

(2.1235%)

since

2025/06/30

6.

Morgan Stanley - Brokerage Accounts

(1.8204%)

since

2025/06/30

7.

Vanguard Group Inc

(1.3074%)

since

2025/06/30

8.

Armistice Capital, LLC

(1.238%)

since

2025/06/30

9.

Geode Capital Management, LLC

(1.1981%)

since

2025/06/30

10.

Qube Research & Technologies

(0.9439%)

since

2025/06/30

11.

Fidelity Small Cap Index

(0.8973%)

since

2025/06/30

12.

Renaissance Technologies Corp

(0.8796%)

since

2025/06/30

13.

Arrowstreet Capital Limited Partnership

(0.8175%)

since

2025/06/30

14.

iShares Russell 2000 Growth ETF

(0.7896%)

since

2025/08/31

15.

Jupiter Asset Management Limited

(0.7095%)

since

2025/06/30

16.

Northern Trust Corp

(0.6999%)

since

2025/06/30

17.

Lazard Asset Management LLC

(0.6068%)

since

2025/06/30

18.

Jacobs Levy Equity Management, Inc.

(0.5683%)

since

2025/06/30

19.

iShares Biotechnology ETF

(0.5437%)

since

2025/08/31

20.

Readystate Asset Management LP

(0.4998%)

since

2025/06/30

21.

Connor Clark & Lunn Inv Mgmt Ltd

(0.494%)

since

2025/06/30

22.

Lazard US Sm Cap Eq WW Dist EUR

(0.4386%)

since

2025/05/31

24.

Vanguard Russell 2000 ETF

(0.422%)

since

2025/07/31

25.

Rice Hall James & Associates, LLC

(0.4182%)

since

2025/06/30

26.

Schroder Investment Management Group

(0.4162%)

since

2025/06/30

27.

International Biotechnology Ord

(0.4062%)

since

2025/07/31

28.

State St Russell Sm Cap® Indx SL Cl I

(0.2987%)

since

2025/08/31

29.

Vanguard Health Care ETF

(0.2741%)

since

2025/07/31

30.

Janus Henderson Small Cap Gr Alpha ETF

(0.2731%)

since

2025/08/29

31.

Hussman Strategic Market Cycle Fund

(0.2583%)

since

2025/06/30

32.

Jupiter Merian Glb Eq AbsRet I USD Acc

(0.2452%)

since

2025/06/30

33.

Schwab Small Cap Index

(0.2286%)

since

2025/07/31

34.

NT R2000 Index Fund - NL

(0.2166%)

since

2025/06/30

35.

US Equity Small Cap Corporate Cl OF

(0.1962%)

since

2024/12/31

36.

Nordea 2 - BetaPlus Enh GlSCap Eq BI USD

(0.1883%)

since

2025/07/31

37.

US Equity Small Cap Pool A

(0.1744%)

since

2024/12/31

38.

NT R2000 Index Fund - DC - NL - 3

(0.1727%)

since

2025/06/30

39.

Avantis US Small Cap Equity ETF

(0.1647%)

since

2025/08/30

40.

Schwab Small-Cap Equity

(0.1635%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.1533

Latest Release

Date

2025-09-30

EPS Actual

0.23

EPS Estimate

0.16

EPS Difference

0.07

Surprise Percent

43.75%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(9)
GARP
Strong GARP(6.5)
Growth
Moderate Growth(5)
Momentum
Moderate Momentum(4)
Net Net
Possible Net-Net(4)
Quality
High Quality(8.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.